Allgenesis Biotherapeutics

Focus: Allgenesis Biotherapeutics is a small-molecule focused biotech startup based in Taipei, Taiwan, founded in 2019 with a team of 1-50 employees. The company operates as a private pre-revenue biotech with no disclosed therapeutic focus areas or clinical pipeline.

Ophthalmology

Profile data last refreshed Yesterday · AI intelligence enriched 2w ago

Funding Stage

PRIVATE

Employees

1-50

Open Jobs

About Allgenesis Biotherapeutics

AI assessmentNot Hiring

No open roles listed right now. Follow Allgenesis Biotherapeutics to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthSolid

Pipeline

Early-stage

3 total

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

AG-80308

Dry Eye Disease

Phase 1

Clinical Trials (1)

NCT05372107A Study of AG-80308 in Dry Eye Patients

Phase 1

Help build intelligence for Allgenesis Biotherapeutics

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Early-stage startup opportunity with potential for significant equity upside in a small, focused team environment
Small molecule focus aligns with a proven, validated drug modality with established regulatory pathways
Taiwan-based biotech operations may offer lower cost-of-living and access to emerging APAC biotech ecosystem

Watch Out For

Zero active clinical trials and no disclosed pipeline programs signal extremely early stage with uncertain business validation
No funding data, revenue, or hiring activity reported; minimal visibility into financial stability or growth trajectory
Company has published no peer-reviewed science and shows no active job openings, suggesting limited growth or operational activity

Generated by Claude from Allgenesis Biotherapeutics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

0.1% AG-86893 Eye Drops

Pterygium

Phase 2

Clinical Trials (1)

NCT03533244A Study of the Response to AG-86893 in Patients With Pterygium Hyperemia

Phase 2

AG-73305

Diabetic Macular Edema

Phase 2

Clinical Trials (1)

NCT05301751A Single Ascending Dose Cohort Study of AG-73305 in DME Patients

Phase 2

Open Jobs (0)

No open positions listed yet.

Interview Prep Quick Facts

Founded: 2019

Portfolio: 3 clinical trials

Top TAs: Ophthalmology

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo

Therapeutic Area Focus

Ophthalmology

1 pipeline

Marketed

Pipeline